XML 38 R30.htm IDEA: XBRL DOCUMENT v3.25.1
Stock-Based Compensation (Tables)
3 Months Ended
Mar. 31, 2025
Share-Based Payment Arrangement [Abstract]  
Schedule of share option activity and related information for employees and directors

The following is a summary of the Company’s stock option activity under the 2014 Equity Incentive Plan, 2023 Equity Incentive Plan and the Peak Bio 2022 Long Term Incentive Plan for the three months ended March 31, 2025:

 

 

Stock
Options

 

 

Weighted-
Average
Exercise
Price

 

 

Weighted-Average
Remaining
Contractual Life
(in years)

 

 

Aggregate
Intrinsic
Value

 

Outstanding at December 31, 2024

 

 

3,963,964,688

 

 

$

0.01

 

 

 

7.5

 

 

$

 

Granted

 

 

10,452,672,000

 

 

 

 

 

 

 

 

 

 

Exercised

 

 

 

 

 

 

 

 

 

 

 

 

Forfeited

 

 

(26,350,000

)

 

 

0.03

 

 

 

 

 

 

 

Expired

 

 

 

 

 

 

 

 

 

 

 

 

Outstanding at March 31, 2025 (1)

 

 

14,390,286,688

 

 

$

 

 

 

9.3

 

 

$

1

 

Exercisable at March 31, 2025

 

 

1,604,153,355

 

 

$

0.01

 

 

 

4.3

 

 

$

1

 

___________

(1)
Includes both vested stock options as well as unvested stock options for which the requisite service period has not been rendered but that are expected to vest based on achievement of a service condition.
Schedule of assumptions used to determine the fair value of stock granted

The weighted-average assumptions that the Company used to determine the fair value of share options granted were as follows, presented on a weighted average basis:

 

 

 

2025

 

 

2024

 

Expected volatility

 

 

95.7

%

 

 

 

Risk-free interest rate

 

 

4.0

%

 

 

 

Expected dividend yield

 

 

 

 

 

 

Expected term (in years)

 

 

5.8

 

 

 

 

Schedule of stock-based compensation expense in the following expense categories of its consolidated statements of operations and comprehensive loss Total stock-based compensation expense attributable to share-based payments made to employees, consultants and directors included in operating expenses in the Company's condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2025 and 2024, was as follows:

 

 

 

Three Months Ended March 31,

 

($ in thousands)

 

2025

 

 

2024

 

Research and development

 

$

191

 

 

$

43

 

General and administrative

 

 

824

 

 

 

253

 

Total stock-based compensation expense

 

$

1,015

 

 

$

296